Cargando…
Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts?
Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373826/ https://www.ncbi.nlm.nih.gov/pubmed/35966579 http://dx.doi.org/10.7150/thno.73400 |
_version_ | 1784767670005006336 |
---|---|
author | Słomka, Artur Wang, Bingduo Mocan, Tudor Horhat, Adelina Willms, Arnulf G. Schmidt-Wolf, Ingo G.H. Strassburg, Christian P. Gonzalez-Carmona, Maria A. Lukacs-Kornek, Veronika Kornek, Miroslaw T. |
author_facet | Słomka, Artur Wang, Bingduo Mocan, Tudor Horhat, Adelina Willms, Arnulf G. Schmidt-Wolf, Ingo G.H. Strassburg, Christian P. Gonzalez-Carmona, Maria A. Lukacs-Kornek, Veronika Kornek, Miroslaw T. |
author_sort | Słomka, Artur |
collection | PubMed |
description | Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be a game changer in cancer diagnosis or cancer screening. But, during their clinical use limitations were observed from statistical significance and questions raised regarding their robustness, that eventually led to be dropped from associated clinical guidelines for certain applications including cancer diagnosis. The purpose of this review isn't to give a broad overview of all current liquid biopsy as biomarkers, weight them and promise a brighter future in cancer prevention, but rather to take a deeper look on two of those who do qualify to be called liquid biopsies now or then. These two are probably of greatest interest conceptually and methodically, and likely have the highest chances to be in clinical use soon, with a portfolio extension over their original conceptual usage. We aim to dig deeper beyond cancer diagnosis or cancer screening. Actually, we aim to review in depth extracellular vesicles (EVs) and compare with circulating tumour cells (CTCs). The latter methodology is partially FDA approved and in clinical use. We will lay out similarities as taking advantage of surface antigens on EVs and CTCs in case of characterization and quantification. But drawing readers' attention to downstream application based on capture/isolation methodology and simply on their overall nature, here apparently being living material eventually recoverable as CTCs are vs. dead material with transient effects on recipient cell as in case of EVs. All this we try to bring in perspective, compare and conclude towards which future direction we are aiming for, or should aim for. Do we announce a winner between CTCs vs EVs? No, but we provide good reasons to intensify research on them. |
format | Online Article Text |
id | pubmed-9373826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-93738262022-08-12 Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? Słomka, Artur Wang, Bingduo Mocan, Tudor Horhat, Adelina Willms, Arnulf G. Schmidt-Wolf, Ingo G.H. Strassburg, Christian P. Gonzalez-Carmona, Maria A. Lukacs-Kornek, Veronika Kornek, Miroslaw T. Theranostics Review Liquid biopsies do promise a lot, but are they keeping it? In the past decade, additional novel biomarkers qualified to be called like that, of which, some took necessary hurdles resulting in FDA approval and clinical use. Some others are since a while around, well known and were once regarded to be a game changer in cancer diagnosis or cancer screening. But, during their clinical use limitations were observed from statistical significance and questions raised regarding their robustness, that eventually led to be dropped from associated clinical guidelines for certain applications including cancer diagnosis. The purpose of this review isn't to give a broad overview of all current liquid biopsy as biomarkers, weight them and promise a brighter future in cancer prevention, but rather to take a deeper look on two of those who do qualify to be called liquid biopsies now or then. These two are probably of greatest interest conceptually and methodically, and likely have the highest chances to be in clinical use soon, with a portfolio extension over their original conceptual usage. We aim to dig deeper beyond cancer diagnosis or cancer screening. Actually, we aim to review in depth extracellular vesicles (EVs) and compare with circulating tumour cells (CTCs). The latter methodology is partially FDA approved and in clinical use. We will lay out similarities as taking advantage of surface antigens on EVs and CTCs in case of characterization and quantification. But drawing readers' attention to downstream application based on capture/isolation methodology and simply on their overall nature, here apparently being living material eventually recoverable as CTCs are vs. dead material with transient effects on recipient cell as in case of EVs. All this we try to bring in perspective, compare and conclude towards which future direction we are aiming for, or should aim for. Do we announce a winner between CTCs vs EVs? No, but we provide good reasons to intensify research on them. Ivyspring International Publisher 2022-08-01 /pmc/articles/PMC9373826/ /pubmed/35966579 http://dx.doi.org/10.7150/thno.73400 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Słomka, Artur Wang, Bingduo Mocan, Tudor Horhat, Adelina Willms, Arnulf G. Schmidt-Wolf, Ingo G.H. Strassburg, Christian P. Gonzalez-Carmona, Maria A. Lukacs-Kornek, Veronika Kornek, Miroslaw T. Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? |
title | Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? |
title_full | Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? |
title_fullStr | Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? |
title_full_unstemmed | Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? |
title_short | Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? |
title_sort | extracellular vesicles and circulating tumour cells - complementary liquid biopsies or standalone concepts? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373826/ https://www.ncbi.nlm.nih.gov/pubmed/35966579 http://dx.doi.org/10.7150/thno.73400 |
work_keys_str_mv | AT słomkaartur extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT wangbingduo extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT mocantudor extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT horhatadelina extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT willmsarnulfg extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT schmidtwolfingogh extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT strassburgchristianp extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT gonzalezcarmonamariaa extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT lukacskornekveronika extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts AT kornekmiroslawt extracellularvesiclesandcirculatingtumourcellscomplementaryliquidbiopsiesorstandaloneconcepts |